Search for Initial Therapy in HIV/AIDS Clinical Care

Physician-authored summaries on the latest research on initial therapy, editorials on initial therapy, and perspectives on initial therapy - drawn from the top medical journals.

Sort by:

Relevance
Date

Items 1 to 20 of 72 results

You searched for: initial therapy in HIV/AIDS

Report from the 2008 Joint ICAAC/IDSA Meeting Free
- November 10, 2008
- HIV/AIDS
The most important HIV-related findings from this year’s meeting
- Related Searches: abacavir/lamivudine, anti-retroviral agents, artemis, atazanavir, benchmrk, benchmrk, bevirimat, castle, darunavir, drug resistance, viral, efavirenz, hiv, hiv, ccr5-tropic, lopinavir/ritonavir, maraviroc, MERIT, mortality, raltegravir
Early Virologic Failure with Tenofovir/FTC + Nevirapine as Initial Therapy Free
- April 14, 2008
- Paul E. Sax, MD
- HIV/AIDS
Investigators stopped a clinical study when three of seven patients receiving tenofovir/FTC + nevirapine experienced early virologic rebound; each had evidence of multiclass viral resistance.
- Reviewing:
- Lapadula G et al., Clin Infect Dis 2008 Apr 1; 46:1127.
- Related Searches: anti-retroviral agents, atazanavir, hiv, nevirapine, tenofovir/emtricitabine
Efavirenz vs. Lopinavir/Ritonavir for Initial Therapy
- February 1, 2005
- Keith Henry, MD
- HIV/AIDS
In a small nonrandomized study, open-label treatment with efavirenz and lopinavir/ritonavir resulted in similar peak CD4 counts and rates of virologic suppression; the efavirenz group had a higher CD4 count and a lower rate of AIDS at baseline.
- Reviewing:
- Manfredi R et al., AIDS 2004 Nov 19; 18:2331-3.
- Related Searches: acquired immunodeficiency syndrome, cd4 count determination procedure, efavirenz, hiv, lopinavir/ritonavir
Can Lopinavir/Ritonavir Be Dosed Once-Daily in Initial Therapy?
- March 1, 2004
- Bruce Soloway, MD
- HIV/AIDS
A small study suggests that once-daily and twice-daily lopinavir/ritonavir administration produce comparable clinical outcomes in treatment-naive patients, although other questions about once-daily dosing remain unanswered.
- Reviewing:
- Eron JJ et al., J Infect Dis 2004 Jan 15; 189:265-72.
Maraviroc for Initial Treatment of HIV Infection — MERIT Reexamined Free
- March 29, 2010
- Charles B. Hicks, MD
- HIV/AIDS
Maraviroc proved noninferior to efavirenz among treatment-naive patients but is still unlikely to see much use in this population.
- Reviewing:
- Cooper DA et al., J Infect Dis 2010 Mar 15; 201:803.
- Related Searches: antagonists, ccr5, efavirenz, hiv, hiv, ccr5-tropic, maraviroc, MERIT
Maraviroc Now Approved for Use in Treatment-Naive HIV-Infected Patients
- December 7, 2009
- Charles B. Hicks, MD
- HIV/AIDS
The new indication maximizes the number of patients who could benefit from maraviroc, but many clinicians and patients will likely opt for agents that are simpler to use.
- Related Searches: hiv, hiv, ccr5-tropic, maraviroc, MERIT
Maraviroc in Treatment-Experienced and Treatment-Naive Patients Free
- September 10, 2007
- Charles B. Hicks, MD
- HIV/AIDS
Data presented at the 4th IAS Conference confirm the value of maraviroc for treatment-experienced patients, but its role in treatment-naive patients remains uncertain.
- Related Searches: anti-retroviral agents, chemokine (c-c motif) receptor 5, efavirenz, hiv, international aids conference, maraviroc, MERIT, MOTIVATE
Standard Triple-Drug Regimens Remain the Best for Initial Therapy Free
- December 29, 2006
- HIV/AIDS
Efavirenz-based regimens appear to be particularly effective.
- Related Searches: abacavir/lamivudine, anti-retroviral agents, efavirenz, fosamprenavir, hiv, lopinavir, lopinavir/ritonavir, protease inhibitor, reverse transcriptase inhibitors, ritonavir
NNRTIs More Durable Than PIs as Initial Therapy
- December 1, 2004
- Keith Henry, MD
- HIV/AIDS
In this prospective observational study, initial NNRTI-based combination therapy led to fewer regimen changes than did initial PI-based combination therapy.
- Reviewing:
- Klein MB et al. , AIDS 2004 Sep 24; 18:1895-904.
Abacavir as Initial Therapy and as a Once-Daily Drug
- November 1, 2003
- Paul E. Sax, MD
- HIV/AIDS
Preliminary results from two industry-sponsored studies suggested that abacavir -- currently used most commonly in treatment-experienced patients -- could be used in combination with 3TC and efavirenz as part of an initial antiretroviral regimen.
NNRTIs Best PIs . . . Again Free
- January 8, 2007
- Paul E. Sax, MD
- HIV/AIDS
In a large randomized trial of treatment-naive patients, the most virologically active strategy was two NRTIs plus an NNRTI; a triple-class strategy yielded greater toxicity but not greater efficacy.
- Reviewing:
- MacArthur RD et al., Lancet 2006 Dec 16; 368:2125-35. Abgrall S., Lancet 2006 Dec 16; 368:2107-9.
- Related Searches: anti-retroviral agents, efavirenz, hiv, nelfinavir, nevirapine, reverse transcriptase inhibitors
ACTG 384 -- Complicated, but Worth the Work
- January 1, 2004
- Paul E. Sax, MD
- HIV/AIDS
In this large, multicenter study comparing 6 different initial treatment strategies, AZT + 3TC + efavirenz emerged clearly superior to the other 5 combinations, including 4-drug triple-class regimens.
- Reviewing:
- Robbins GK et al., N Engl J Med 2003 Dec 11; 349:2293-303. Shafer RW et al., N Engl J Med 2003 Dec 11; 349:2304-15. Skolnik PR et al., N Engl J Med 2003 Dec 11; 349:2351-2.
Revised HIV Treatment Guidelines from the DHHS Free
- October 31, 2011
- Abigail Zuger, MD
- HIV/AIDS
This revision focuses on treatment choices for antiretroviral-naive patients.
- Reviewing:
- Panel on Antiretroviral Guidelines for Adults and Adolescents., 2011 Oct 14;:
- Related Searches: guidelines, hiv
Etravirine and Efavirenz Show Similar Virologic Efficacy
- September 12, 2011
- Paul E. Sax, MD
- HIV/AIDS
In a randomized, double-blind trial, response rates were around 75% for both treatments.
- Reviewing:
- Gazzard B et al., AIDS 2011 Aug 30;:
- Related Searches: efavirenz, etravirine, hiv
Tenofovir/FTC/Rilpivirine: A New One-Pill, Once-Daily Option for HIV Treatment
- August 15, 2011
- Paul E. Sax, MD
- HIV/AIDS
The fixed-dose combination was just approved by the FDA for use in treatment-naive HIV-infected individuals.
- Related Searches: echo, efavirenz, efavirenz/tenofovir/emtricitabine, hiv, hiv infection, hiv-1, hiv-1 infection, rilpivirine, tenofovir/emtricitabine, thrive
HIV/AIDS Year in Review 2010
- January 3, 2011
- Paul E. Sax, MD
- HIV/AIDS
Our physician-editors offer their perspective on the year's most important stories in HIV medicine.
- Related Searches: anti-retroviral agents, hiv, hiv prevention
HIV Drug Pipeline Promises More Fixed-Dose Combinations Free
- January 4, 2010
- Helmut Albrecht, MD
- HIV/AIDS
By 2011, providers and patients may be able to choose between several "one-pill, once-daily" options.
- Related Searches: anti-retroviral agents, bevirimat, drug development, elvitegravir , gsk572, hiv, hiv integrase inhibitors, polycap, rilpivirine
HIV Resistance Testing — Valuable but Far from Universal
- November 23, 2009
- Charles B. Hicks, MD
- HIV/AIDS
Testing rates increased over time in two cohorts of HIV-infected patients but were low among women, heterosexuals, older patients, and blacks.
- Reviewing:
- Buchacz K et al., J Acquir Immune Defic Syndr 2009 Oct 16;: Bansi L et al., J Acquir Immune Defic Syndr 2009 Oct 21;:
- Related Searches: anti-retroviral agents, drug resistance, viral, genetic test, hiv, hops
Ritonavir-Boosted Saquinavir Is Comparable to Lopinavir/r in Treatment-Naive Patients
- May 4, 2009
- Paul E. Sax, MD
- HIV/AIDS
Ritonavir-boosted saquinavir was noninferior to lopinavir/r in an international trial but currently offers few advantages over other PIs.
- Reviewing:
- Walmsley S et al., J Acquir Immune Defic Syndr 2009 Apr 1; 50:367.
- Related Searches: hiv, hiv protease inhibitors, lopinavir/ritonavir, ritonavir, saquinavir
Investigational Pharmacologic Boosters
- March 9, 2009
- Charles B. Hicks, MD
- HIV/AIDS
Two promising alternatives to ritonavir were described at this year’s Retrovirus Conference.
- Related Searches: anti-retroviral agents, drug potentiation, gs-9350, hiv, hiv protease inhibitors, ritonavir, spi-452

Sort by:

Relevance
Date

Items 1 to 20 of 72 results

Search

Sign-In

Forgot your password? Login via Athens
or your institution

Search for Initial Therapy in HIV/AIDS Clinical Care

Report from the 2008 Joint ICAAC/IDSA Meeting Free

Early Virologic Failure with Tenofovir/FTC + Nevirapine as Initial Therapy Free

Efavirenz vs. Lopinavir/Ritonavir for Initial Therapy

Can Lopinavir/Ritonavir Be Dosed Once-Daily in Initial Therapy?

Maraviroc for Initial Treatment of HIV Infection — MERIT Reexamined Free

Maraviroc Now Approved for Use in Treatment-Naive HIV-Infected Patients

Maraviroc in Treatment-Experienced and Treatment-Naive Patients Free

Standard Triple-Drug Regimens Remain the Best for Initial Therapy Free

NNRTIs More Durable Than PIs as Initial Therapy

Abacavir as Initial Therapy and as a Once-Daily Drug

NNRTIs Best PIs . . . Again Free

ACTG 384 -- Complicated, but Worth the Work

Revised HIV Treatment Guidelines from the DHHS Free

Etravirine and Efavirenz Show Similar Virologic Efficacy

Tenofovir/FTC/Rilpivirine: A New One-Pill, Once-Daily Option for HIV Treatment

HIV/AIDS Year in Review 2010

HIV Drug Pipeline Promises More Fixed-Dose Combinations Free

HIV Resistance Testing — Valuable but Far from Universal

Ritonavir-Boosted Saquinavir Is Comparable to Lopinavir/r in Treatment-Naive Patients

Investigational Pharmacologic Boosters

Search

New to Journal Watch?